Acute urinary retention

Active substance:

Content

Pharmacological group

Nosological classification (ICD-10)

3D images

Description of the dosage form

Tablets: white flat-cylindrical in shape with a facet and risky.

pharmachologic effect

Pharmacodynamics

The spectrum of action is associated with the presence in the structure of GABA. The mechanism of action is due to the direct effect of Pantokalcin ® on the GABAH receptor-channel complex. It has neurometabolic, neuroprotective and neurotrophic properties. Increases the brain’s resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons. Possesses anticonvulsant action, reduces motor excitability with simultaneous streamlining of behavior. Enhances mental and physical performance. Contributes to the normalization of GABA in chronic alcohol intoxication and the subsequent abolition of ethanol. Shows analgesic effect. Able to inhibit acetylation reactions involved in the inactivation mechanisms of novocaine and sulfonamides, which results in a prolonged action of the latter. It causes inhibition of the pathologically increased gallbladder reflex and detrusor tone.

Pharmacokinetics

When ingestion is rapidly absorbed from the gastrointestinal tract. Tmax in blood plasma is 1 hour. The highest concentrations are created in the liver, kidneys, stomach wall, and skin. Gets through the BBB. Not metabolized and excreted unchanged for 48 hours (67.5% of the dose – with urine, 28.5% – with feces).

Indications drug Pantokalcin ®

cognitive impairment in organic brain lesions and neurotic disorders;

as part of the treatment of cerebrovascular insufficiency caused by atherosclerotic changes of cerebral vessels; senile dementia (initial form), residual organic brain damage in people of mature age and the elderly;

cerebral organic deficiency in patients with schizophrenia (in combination with antipsychotics, antidepressants);

extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (in

consequences of postponed neuroinfections and traumatic brain injuries (as part of complex therapy);

correction and prevention (cover therapy with simultaneous appointment) side effects of neuroleptics; extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic);

epilepsy with a slowdown in mental processes (in combination with anticonvulsants);

psycho-emotional overload, reduced mental and physical performance; to improve concentration and memorization;

urination disorders: enuresis, daytime incontinence, pollakiuria, imperative urges;

mental retardation (delayed mental, speech, motor development, or a combination thereof);

cerebral palsy;

stuttering (predominantly clonic form);

epilepsy (as part of combination therapy with anticonvulsants, especially during polymorphic seizures and minor epileptic seizures).

Contraindications

acute renal failure;

pregnancy (I term).

Use during pregnancy and lactation

Contraindicated in the first trimester of pregnancy.

Side effects

Allergic reactions (rhinitis, conjunctivitis, skin rashes) are possible.

Interaction

It prolongs the action of barbiturates; enhances the effects of drugs that stimulate the central nervous system, anticonvulsant drugs, the action of local anesthetics (procaine). It prevents the side effects of the following drugs: phenobarbital, carbamazepine, antipsychotics (neuroleptics).

The effect of hopantenic acid is enhanced in combination with glycine, ksifiponom.

Dosage and administration

Take 15-30 minutes after eating.

The single dose for adults is 0.5–1 g, for children – 0.25–0.5 g, daily – 1.5–3 g (for adults), 0.75–3 g (for children). The duration of treatment is from 1 to 4 months, in some cases – up to 6 months. After 3–6 months, a repeated course of treatment is possible.

Children. Mental deficiency – 0.5 g 4–6 times a day, daily for 3 months. Delayed speech development – 0.5 g 3-4 times a day for 2-3 months.

Neuroleptic syndrome (as a corrector side effects of antipsychotic drugs). Adults – 0.5–1 g 3 times a day; children – 0.25–0.5 g 3-4 times a day. Duration of treatment is 1–3 months.

Epilepsy. Children – 0.25–0.5 g 3-4 times a day; adults, 0.5–1 g 3-4 times a day, daily for a long time (up to 6 months).

Acute urinary retention

Hyperkinesis (tiki). Children – 0.25–0.5 g 3–6 times a day every day for 1–4 months; adults, 1.5–3 g daily for 1–5 months.

Urinary Disorders. Adults – 0.5–1 g 2–3 times a day (daily dose – 2–3 g); children – 0.25–0.5 g each (daily dose – 25–50 mg / kg). The duration of treatment is from 2 weeks to 3 months (depending on the severity of the disorder and the therapeutic effect).

Consequences of neuroinfections and head injuries. 0.25 g 3-4 times a day.

To restore performance at high loads and asthenic conditions. 0.25 g 3 times a day.

Acute urinary retention

This dosage form is not recommended for children under 3 years.

Release form

Tablets, 250 mg, 500 mg. In blisters made of PVC film and aluminum foil, 10 pcs. Each. In polymer cans complete with covers of 50 pcs. In a carton pack 5 packs or 1 bank.

Manufacturer

OAO Valenta Pharmaceutics. 141101, Moscow region, Schelkovo, ul. Factory, 2.

Tel: (495) 933-48-62; fax: (495) 933-48-63.

Pharmacy sales terms

Storage conditions drug Pantokalcin ®

Keep out of the reach of children.

The shelf life of the drug Pantokalcin ®

Do not use after the expiration date printed on the package.

Like this post? Please share to your friends:
Leave a Reply